London Researchers have identified an increase in Guillain-Barre syndrome cases as a result of the AstraZeneca vaccine. The initial dosage of the AstraZeneca vaccine has been linked to a small but considerable increase in the incidence of the dangerous neurological illness Guillain-Barre syndrome (GBS), it said.
The cause of the association, according to researchers at University College London (UCL), is yet unknown. They did highlight, however, that the limited number of GBS cases observed appear to be similar to increases seen in prior large immunisation efforts.
Guillain-Barre syndrome (GBS) is an uncommon but deadly autoimmune disease that affects the peripheral nerve system, causing numbness, weakness, and discomfort in the limbs, as well as respiratory paralysis in certain cases. Pfizer's Covid-19 vaccine was launched in December 2020 in the United Kingdom, followed by AstraZeneca in January 2021 and Moderna in April 2021.
Researchers found that 996 GBS cases were reported in the UK between January and October 2021, with an unusual surge in GBS reports occurring between March and April 2021, according to the study published in the journal Brain. There were around 140 cases per month during these two months, compared to about 100 cases per month in the past.
In England, 198 GBS cases (20% of 966) occurred within six weeks of the first-dose Covid-19 vaccine, equal to 0.618 cases per 100,000 vaccinations, according to the research.
If you have type-2 diabetes, you should consume aloe vera in this way, it will be beneficial
Not only cancer, but Consuming Tobacco can also cause these serious diseases
If you are getting constipated again and again then you may have cancer